Quantcast
Home > Quotes > VSTM
VSTM

Verastem, Inc. Common Stock (VSTM) Quote & Summary Data

$5.075
*  
0.435
7.89%
Get VSTM Alerts
*Delayed - data as of Nov. 12, 2018  -  Find a broker to begin trading VSTM now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    VSTM After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 5.05 / $ 5.15
Today's High / Low
$ 5.50 / $ 4.92
Share Volume
1,765,717
50 Day Avg. Daily Volume
3,375,701
Previous Close
$ 5.51
52 Week High / Low
$ 10.35 / $ 2.77
Market Cap
374,231,348
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
1,765,717
50 Day Avg. Daily Volume:
3,375,701

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.43

Trading Range

The current last sale of $5.075 is 83.21% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 5.50 $ 10.35
 Low: $ 4.92 $ 2.77

Company Description (as filed with the SEC)

We are a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. Our most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. We are currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. We believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a central role in cancer proliferation and survival.  ... More ...  


Risk Grade

Where does VSTM fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 5.50
Open Date:
Nov. 12, 2018
Close Price:
$ 5.51
Close Date:
Nov. 9, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x